REDWOOD CITY, CA, Karius, a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding.
The round was co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare. Also investing was new investor Seventure Partners, and existing investors Softbank Vision Fund 2, General Catalyst, HBM Healthcare Investments, Blue Water Life Sciences, Innovation Endeavors, Waycross Ventures, and others.
Karius, a global leader in liquid biopsy for infectious diseases, harnesses metagenomics, next-generation sequencing, and artificial intelligence (AI) to help enhance the precision and speed of pathogen diagnosis. The Karius Test®, used in over 400 healthcare institutions-including 90+ transplant centers and 40+ children's hospitals across the United States-identifies more than 1,000 pathogens, including viruses, bacteria, fungi, and parasites from a single blood draw typically within a day of sample receipt.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
